El Ethics and Drug Research Committee (CEIm) of Parc Taulí has been reclassified as the 4th in Spain and 3rd in Catalonia in the activity carried out to evaluate clinical trials with medicines during 2023, according to the ranking produced annually by theSpanish Agency for Medicines and Health Products (AEMPS).
The list, led by the CEIm of the Hospital General Universitari Gregorio Marañón de Madrid, ranks the 25 state committees that have carried out the most evaluations of clinical trials with medicines carried out in humans. These 25 organizations are responsible for 90% of the evaluation activity currently carried out throughout Spain.
Specifically, Parc Taulí evaluated a total of 62 projects with clinical trials with medicines last year, which represents a 7% of the total number of projects of this nature assessed throughout 2023 in the country.
In such a competitive environment, continuing to maintain ourselves as one of the best committees in Spain gives value to the work that the entire technical secretariat of the CEIm does on a daily basis and reflects the trust placed in us by the medical community", says Miquel Àngel Seguí, president of the CEIm and coordinator of the cancer research area of the Parc Taulí Research and Innovation Institute (I3PT).
According to Seguí, the excellent results achieved "cannot be explained without highlighting the great adaptability of the team". And it is that, from the beginning of 2023, it is mandatory to carry out the evaluation of clinical trials with medicines in a coordinated manner with the rest of the countries of Europe through the Clinical Trials Information System (CTIS), a database that has been developed to harmonize the process of application, evaluation and supervision of clinical trials in the European Economic Area. In this context, the CEIm of Parc Taulí is one of the country's committees aligned with this new evaluation framework.
Since it was accredited for the first time in 1994 - and subsequently renewed every 4 years - the CEIm of Parc Taulí has become one of the most active nationally in the evaluation of clinical studies. Only in the period of 2020 to 2023, the committee chaired by Seguí has assessed 256 clinical trials with drugs, contributing significantly to the progress of medical research and the development of new therapies to improve the health and well-being of patients.
The functions of the CEIm
The CEIm are accredited independent bodies, in accordance with Royal Decree 1090/2015, to evaluate and issue opinions on clinical studies with medicines and clinical research with health products.
Specifically, a CEIm evaluates all that research that has as its purpose the development of drugs for use in people. Based on this, it issues an opinion on the trial protocol, the suitability of the research team and facilities, as well as the methodology and documents to be used to inform the people participating in the trial .
CEIm also monitors the clinical trial from start to finish.
ZAP
Zaproxy dolore alias impedit expedita quisquam.